NUVASIVE ANTERIOR LUMBAR PLATE SYSTEM

K111866 · Nuvasive, Inc. · KWQ · Jul 22, 2011 · Orthopedic

Device Facts

• Record ID: K111866
• Device Name: NUVASIVE ANTERIOR LUMBAR PLATE SYSTEM
• Applicant: Nuvasive, Inc.
• Product Code: KWQ · Orthopedic
• Decision Date: Jul 22, 2011
• Decision: SESE
• Submission Type: Special
• Regulation: 21 CFR 888.3060
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The NuVasive Halo II Anterior Lumbar Plate System is indicated for use via a lateral or anterolateral surgical approach above the bifurcation of the great vessels in the treatment of thoracic and thoracolumbar (T1-L5) spine instability or via the anterior surgical approach, below the bifurcation of the great vessels in the treatment of lumbar and lumbosacral (L1-S1) spine instability as a result of fracture (including dislocation and subluxation), tumor, degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), scoliosis, kyphosis, lordosis, spinal stenosis, or a failed previous spine surgery.

Device Story

The NuVasive Halo II Anterior Lumbar Plate System is a spinal fixation implant system. It consists of plates and screws used to provide stabilization to the thoracic, thoracolumbar, lumbar, and lumbosacral spine. The device is implanted by a surgeon during a lateral, anterolateral, or anterior surgical approach. It functions as an internal fixation orthosis to address spinal instability caused by various pathologies, including fractures, tumors, and degenerative conditions. The system provides mechanical support to the spine to facilitate stabilization.

Clinical Evidence

Bench testing only. Static and dynamic compression testing and static torsion testing were performed in accordance with ASTM F1717 to demonstrate mechanical equivalence to predicate devices.

Technological Characteristics

Materials: Ti-6Al-4V (ASTM F-136, ISO 5832-3) and Nitinol alloy SE508 (ASTM F2063). System consists of plates and screws. Mechanical testing performed per ASTM F1717.

Indications for Use

Indicated for patients requiring stabilization of the thoracic, thoracolumbar (T1-L5), lumbar, or lumbosacral (L1-S1) spine due to fracture, tumor, degenerative disc disease, scoliosis, kyphosis, lordosis, spinal stenosis, or failed previous surgery.

Regulatory Classification

Identification

A spinal intervertebral body fixation orthosis is a device intended to be implanted made of titanium. It consists of various vertebral plates that are punched into each of a series of vertebral bodies. An eye-type screw is inserted in a hole in the center of each of the plates. A braided cable is threaded through each eye-type screw. The cable is tightened with a tension device and it is fastened or crimped at each eye-type screw. The device is used to apply force to a series of vertebrae to correct “sway back,” scoliosis (lateral curvature of the spine), or other conditions.

Predicate Devices

• NuVasive, Inc. Anterior Lumbar Plate System (K072339)
• Depuy Spine AEGIS Anterior Lumbar Plate System (K052546)

Submission Summary (Full Text)

{0}------------------------------------------------

K111866

Image /page/0/Picture/1 description: The image shows the Nuvasive logo. The logo consists of a stylized eye-like shape on the left and the word "NUVASIVE" on the right. Below the word "NUVASIVE" is the phrase "speed of innovation" in a smaller font.

510(k) Premarket Notification Halo II Anterior Lumbar Plate System

# 510(k) Summary

2 2 2011 In accordance with Title 21 of the Code of Federal Regulations, Part 807, and in particular 21 CFR §807.92, the following summary of information is provided:

### A. Submitted by:

Sheila Bruschi Associate Manager, Regulatory Affairs NuVasive, Incorporated 7475 Lusk Blvd. San Diego, California 92121 [phone]

Date Prepared: July 20, 2011

### B. Device Name

| Trade or Proprietary Name: | NuVasive Halo II Anterior Lumbar Plate System |
|----------------------------|-----------------------------------------------|
| Common or Usual Name: | Anterior, Noncervical Spinal Implant |
| Classification Name: | Spinal Intervertebral Body Fixation Orthosis |

| Device Class: | Class II |
|-----------------|------------------|
| Classification: | 21 CRF §888.3060 |
| Product Code: | KWQ |

#### C. Predicate Devices

The subject NuVasive Halo II Anterior Lumbar Plute System is substantially equivalent to the following devices:

- · K072339 NuVasive, Inc. Anterior Lumbar Plate System
- · K052546 Depuy Spine AEGIS Anterior Lumbar Plate System

### D. Device Description

The NuVasive Halo II Anterior Lumbar Plate System consists of a series of plates and screws manufactured from Ti-6Al-4V per ASTM F-136 and ISO 5832-3. The plates also include components manufactured from Nitinol alloy SE508 per ASTM F2063.

#### E. Intended Use

The NuVasive Halo II Anterior Lumbar Plate System is indicated for use via a lateral or anterolateral surgical approach above the bifurcation of the great vessels in the treatment of thoracic and thoracolumbar (TI-L5) spine instability or via the anterior surgical approach, below the bifurcation of the great vessels in the treatment of lumbar and lumbosacral (L) .-SI) spine instability as a result of fracture (including dislocation and subluxation), tumor, degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), scoliosis, kyphosis, lordosis, spinal stenosis, or a failed previous spine surgery.

{1}------------------------------------------------

K11866

Image /page/1/Picture/1 description: The image shows the logo for Nuvasive. The logo consists of a stylized letter "N" on the left, followed by the word "NUVASIVE" in all caps. Below the word "NUVASIVE" is the tagline "Speed of Innovation" in a smaller font. The logo is simple and modern, and the tagline emphasizes the company's focus on innovation.

# 510(k) Premarket Notification Halo II Anterior Lumbar Plate System

### Technological Characteristics F.

As was established in this submission, the subject Halo II Anterior Lumbar Plate System is substantially equivalent to other predicate devices cleared by the FDA for commercial distribution in the United States. The subject device was shown to be substantially equivalent and have the same technological characteristics to its predicate devices through comparison in areas including design, intended use, material composition, function, and range of sizes.

### G. Performance Data

Nonclinical testing was performed to demonstrate that the subject Halo II Anterior Lumbar Plate System is substantially equivalent to other predicate devices. The following testing was performed:

- . Static and dynamic compression testing per ASTM F1717
- . Static torsion testing per ASTM F1717

The results of these studies show that the subject Halo II Anterior Lumbar Plate System meets or exceeds the performance of the predicate device, and the device was therefore found to be substantially equivalent.

#### H. Conclusions

Based on the indications for use, technological characteristics, performance testing, and comparison to predicate devices, the subject Halo II Anterior Lumbar Plate System has been shown to be substantially equivalent to legally marketed predicate devices, and safe and effective for its intended use.

{2}------------------------------------------------

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health and Human Services. The logo consists of a stylized eagle with three lines representing its wings and body. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" is arranged in a circular fashion around the eagle.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

NuVasive, Inc. % Ms. Sheila Bruschi Associate Manager, Regulatory Affairs 7475 Lusk Boulevard San Diego, California 92121

JULL 2 22 22 2013

Re: K111866

Trade/Device Name: NuVasive Halo II Anterior Lumbar Plate System Regulation Number: 21 CFR 888.3060 Regulation Name: Spinal intervertebral body fixation orthosis Regulatory Class: Class II Product Code: KWQ Dated: June 28, 2011 Received: June 30, 2011

Dear Ms. Bruschi:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21

{3}------------------------------------------------

Page 2 - Ms. Sheila Bruschi

CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely vours.

Kru Dothin Lirir

Mark N. Melkerson Director Division of Surgical, Orthopedic and Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{4}------------------------------------------------

# Indications for Use

510(k) Number (if known): KI | | 866

Device Name:

Indications For Use:

The NuVasive Halo II Anterior Lumbar Plate System is indicated for use via a lateral or anterolateral surgical approach above the bifurcation of the great vessels in the treatment of thoracic and thoracolumbar (T1-L5) spine instability or via the anterior surgical approach, below the bifurcation of the great vessels in the treatment of lumbar and lumbosacral (L1-S1) spine instability as a result of fracture (including dislocation and subluxation), tumor, degenerative disc disease (defined as back pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), scoliosis, kyphosis, spinal stenosis, or a failed previous spine surgery.

Prescription Use X (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

*(Division/Sign-O :)*

Division of Surgi - 1. Orthopedic, and Restorative Levices

KIII866 510(k) Number_